SCHEMBL5139992

SCHEMBL5139992

Cc1cnc(COc2nc(N)nc(-c3ccc(C)o3)c2C#N)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.39
ALDH1A1 P00352 10/20 0.39
HPGD P15428 8/20 0.39
MAPT P10636 7/20 0.39
PKM P14618 6/20 0.39
MEN1 O00255 5/20 0.39
GAA P10253 5/20 0.39
KMT2A Q03164 5/20 0.39
ALOX12 P18054 4/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ADORA2A P29274 8/20 0.37
ADORA1 P30542 2/20 0.37
GLA P06280 3/20 0.37
HSD17B10 Q99714 3/20 0.37
LMNA P02545 2/20 0.37
ALOX15 P16050 2/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441081 0.90 POLB (0.37) KDM4EALDH1A1HPGDMAPTPKM
SCHEMBL5131946 0.85 ADORA2A (0.48) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL5131727 0.85 ADORA2A (0.52) KDM4EALDH1A1HPGDMAPTPKM
SCHEMBL6442327 0.82 HSP90AA1 (0.33) ALDH1A1
SCHEMBL6446348 0.81 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTPKM
SCHEMBL6444357 0.80 SQOR (0.37) KDM4EALDH1A1HPGDMAPTMEN1
SCHEMBL5039926 0.78 ADORA2A (0.52) KDM4EALDH1A1HPGDMAPTPKM
SCHEMBL5040413 0.78 ADORA2A (0.41) KDM4EALDH1A1HPGDMAPTPKM
SCHEMBL5131348 0.75 ADORA2A (0.42) ADORA2AADORA1ADORA2B
SCHEMBL6441503 0.75 ADORA2A (0.42) ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4064671-B2 2008-03-19 JP claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP claimed
JP-2003523380-A 2003-08-05 JP claimed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US claimed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP claimed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US claimed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 KDM4E 3250/4885ALDH1A1 534/4885HPGD 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.